Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

November 17, 2017: By Joan McKenna

A federal judge declared a mistrial Nov. 16 in a federal corruption trial of Florida retina specialist Salomon Melgen and US Sen. Bob Menendez, D-New Jersey, after jurors were unable to reach a verdict. Prosecutors can seek to retry the case.

The trial, overseen by US District Judge William Walls in New Jersey, began Sept. 6. It examined whether Menendez lobbied for Melgen’s business interests in exchange for gifts and political donations.

Defense attorneys built a portrait of their clients as simply friends. Prosecutors alleged that the defendants’ behavior amounted to bribery.

The Justice Department claimed that Menendez intervened to help Melgen try to resolve his $8.9 million billing dispute with Medicare in 2009, after Melgen was accused of overbilling for Lucentis vials. Menendez in return received luxury trips, flights on private jets, and hundreds of thousands of dollars in campaign donations, prosecutors claim.

The judge repeatedly urged jurors to continue deliberating, telling them to “take as much time as you need.”
In a separate trial earlier in 2017, Melgen, 62, was convicted of 67 counts of Medicare fraud. His sentencing hearing was pushed back to December due to the New Jersey trial. Melgen operated the now closed Vitreo-Retinal Consultants of the Palm Beaches.

In that trial, Melgen was accused of falsely diagnosing patients with macular degeneration and other retinal disorders, performing unnecessary procedures, and overcharging for Lucentis by splitting single-use bottles into multiple doses but charging Medicare per patient.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023